What You Should Know:
– Pleno, an innovative multi-omics diagnostics company, announced it has raised $25M in Series B funding and appointed Dr. Vik Vaz as its new Chief Executive Officer (CEO). Key investors Deerfield Management, Foresite Capital and Medical Excellence Capital remain committed to supporting the next phase of the company’s growth strategy.
– Dr. Vaz, a seasoned leader with extensive experience in the life sciences and medical technology sectors, will guide Pleno’s expansion as the company scales its commercial operations.
Dr. Vaz Bio/Background
Dr. Vaz an actively licensed physician with training and experience from prestigious institutions like Harvard Medical School and the University of Miami. Dr. Vaz served most recently as head of strategy and market intelligence and a leader of the companion diagnostics business at Illumina. Prior to that, he has served as a partner at Boston Consulting Group and McKinsey and Company, advising leading pharmaceutical and medical device companies. His leadership and expertise will be instrumental in driving the company’s growth, expanding its reach, and bringing its innovative technology to a wider audience.
“I am excited to be joining Pleno and look forward to leading this exceptional team,” said Dr. Vaz. “We are poised to bring a transformational new technology to market that will improve patient care and drive advances in biological understanding. The data we have generated already will spur impact across oncology, infectious disease and many other clinical applications.”
Pleno is developing the RAPTORTM multi-omic instrument platform, a groundbreaking technology that aims to revolutionize biological target detection. This platform:
- Simplifies multi-omics: Makes complex multi-omic analysis more accessible and affordable.
- Enhances performance: Delivers unprecedented improvements in accuracy and efficiency.
- Reduces costs: Offers a cost-effective solution for life science research and diagnostics.
- Increases scalability: Enables broader adoption of multi-omics across various applications.
